Phase I clinical trial study is ongoing to assess safety and tolerance of PD-L1 and CD80/CD86 targeting CAR-T cells in the treatment of recurrent or refractory NSCLC patients (NCT03060343). The gene discussed is CD86; the disease is non-small cell lung carcinoma.